BASEL, SWITZERLAND — Lonza Group AG, a Swiss specialty chemicals and pharmaceutical ingredients company, has agreed to acquire InterHealth Nutraceuticals, Inc. for up to $300 million.
InterHealth, a Benicia, Calif.-based developer and manufacturer of nutritional ingredients used in dietary supplements, is a portfolio company of Kainos Capital. InterHealth offers more than 15 branded ingredients, such as UC-II, which promotes healthy joints. InterHealth’s offerings will complement Lonza’s existing nutritional portfolio in the areas of sports nutrition, weight management and immune health, Lonza said, as well as extend Lonza’s offerings into new areas such as cognitive and diabetic health.
|Richard Ridinger, c.e.o. of Lonza|
“With this acquisition, Lonza is taking a further step along our strategic path as a high-value supplier to the health care continuum,” said Richard Ridinger, chief executive officer of Lonza. “Lonza will leverage the successful product portfolio of InterHealth on a global level and in turn will be able to benefit from InterHealth’s proven management and branding capabilities to promote Lonza’s existing product portfolio. We see significant positive synergies from this combination.”The transaction, expected to close in September, is projected to be immediately accretive to Lonza’s earnings.